KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

A randomized, non-inferiority phase III clinical trial of immunogenicity and safety of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10-60.

Danhua Zhao, Junshi Zhao, Xiaopan Chen, Lingfeng Yuan, Ping Wang, Leitai Shi, Yunpeng Wang, Jia Li, Lijuan Zhou, Xiaohong Wu, Shilong Yang, Lidong Gao

BMC Infect Dis 25(1) 1756

PMID41466188
PMCIDPMC12751179
DOI10.1186/s12879-025-12075-y
发表日期2025-12-30
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:ROC 图;Fig. 2:CONSORT/入组流程图;Fig. 3:ROC 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图。
摘要

摘要

BACKGROUND: This study aimed to evaluate the safety and immunogenicity of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10–60 METHODS: This study adopts a randomized, double-masked, single-center, non-inferiority trial design with similar vaccines. This phase III clinical trial consisted of two stages, the first stage recruited 80 participants, and the second stage recruited 1,800 participants. In stage 1, 40 participants aged 18–60 years were enrolled to vaccinate with the investigational vaccine firstly, and then 40 people aged 10–17 years were enrolled for safety analysis. The number of participants who received either a 5-dose or a 4-dose immunization regimen was 40. During stage 2, subjects were assigned to 5-dose Essen group, 4-dose Zagreb group, 5-dose control group to conduct rabies virus neutralization antibody detection and adverse events(AEs) collection. RESULTS: In stage 2, 14 days after the initial dose of immunization and 14 days after completing the immunization program, the differences in the seroconversion rates (5-dose Essen group vs. 5-dose control group, 4-dose Zagreb group vs. 5-dose control group) were both 0.00, with the lower limits of the 95% confidence intervals exceeding the non-inferiority margin of −5%. AEs occurred at a total rate of 35.17% in the 5-dose Essen group, 36.50% in the 5-dose control group, and 30.00% in the 4-dose Zagreb group. CONCLUSIONS: The immunogenicity of 5-dose and 4-dose schedules of the freeze-dried human rabies vaccine (MRC-5 cells) was non-inferior to that of the human diploid cell vaccine, and the safety was good after vaccination. TRIALS REGISTRATION: NCT06078423, A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells), “retrospectively registered” on 2023–10-11.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study overview in stage 2. Schematic overview of the study groups and their corresponding study procedures. Blood was drawn pre-vaccination. 35 day/42 day represented 14 days after the completion of the vaccination course; 3 month and 12 month denoted 3 months and 12 months after full vaccination, respectively
非 KM Figure
Fig. 2Flow diagram of the stage 2.The number of subjects who provided baseline blood samples (pre-vaccination) was identical across the three groups and matched the number receiving the first vaccine dose. In the Essen and control groups, the number of participants providing samples at 7 and 14 days after the first dose corresponded to the numbers sampled after the third and fourth doses, respectively. D35/D42 represented 14 days after the completion of the vaccination course; M3 and M12 denoted 3 months and 12 months after full vaccination, respectively
非 KM Figure
Fig. 3Immunogenicity analysis in seronegative participants. GMC ( A ), GMC ratio ( B ), SCR ( C ), difference in SCR ( D ). SCR = seroconversion rate; D7 = 7 days after the first vaccination; D14 = 14 days after the first vaccination; D35/D42 = 14 days after the completion of the vaccination course. Baseline was defined before the first vaccination. Seroconversion was defined as a ≥ 4-fold titer rise or seroconversion from negative to positive (≥0.5 IU/mL). Error bars indicate 95% CIs (GMC/GMC ratio: t-distribution/ANCOVA/ANOVA; SCR: Clopper-Pearson; SCR difference: Miettinen-Nurminen)
非 KM Figure
Fig. 4Immune persistence analysis. SPR = Seropositivity rates; M3 and M12 denoted 3 months and 12 months after full vaccination, respectively
非 KM Figure
Fig. 5Comparison of adverse events between the three groups in stage 2. Solicited systemic adverse reactions ( A ), solicited local reactions ( B ). Percentages of participants who had a solicited local or systemic adverse reaction within 7 days after each dose of vaccination
非 KM Figure